Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life

Simple item page
dc.cibjournal
dc.contributor.authorLaughton, Barbaraen_ZA
dc.contributor.authorNaidoo, Shalenaen_ZA
dc.contributor.authorDobbels, Elsen_ZA
dc.contributor.authorBoivin, Michael J.en_ZA
dc.contributor.authorJanse van Rensburg, Anitaen_ZA
dc.contributor.authorGlashoff, Richard H.en_ZA
dc.contributor.authorVan Zyl, Gert U.en_ZA
dc.contributor.authorKruger, Marianaen_ZA
dc.contributor.authorCotton, Mark F.en_ZA
dc.date.accessioned2020-04-08T06:51:03Z
dc.date.available2020-04-08T06:51:03Z
dc.date.issued2019-10-03
dc.descriptionCITATION: Laughton, B. et al. 2019. Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life. Southern African Journal of HIV Medicine, 20(1):a1008, doi:10.4102/sajhivmed.v20i1.1008.
dc.descriptionThe original publication is available at https://sajhivmed.org.za
dc.description.abstractBackground: Antiretroviral therapy (ART) started between 7 and 12 weeks of age improves neurodevelopmental outcomes in HIV-infected (HIV+) infants, but the impact of even earlier initiation is not yet described. Objectives: We assessed the early neurodevelopment of HIV+ infants who started ART within 21 days of life. Method: Participants were enrolled from the public sector birth HIV-diagnosis programme. Inclusion criteria included the following: birth weight > 2000 g, infant commencing ART < 6 weeks and no infant cytomegalovirus disease. Antiretroviral therapy included Zidovudine/Lamivudine/Nevirapine for the first 2 weeks, the latter then replaced by Lopinavir/Ritonavir. Once body weight > 3 kg and gestational age > 44 weeks, Abacavir replaced Zidovudine. The Griffiths mental development scales (GMDS) were administered at 10–12 months. Results: Of 29 infants assessed, 23 (79%) were girls. Mean birth weight was 3002 ± 501 g. Twenty-four mothers (83%) received ART during pregnancy. Seven (24%) infants were diagnosed HIV+ within 48 h of birth. Median [interquartile range] viral load (VL) at diagnosis was 3904 [259–16 922] copies/mL, age starting ART was 6.0 [3–10] days and age at VL suppression was 19.1 [15–36] weeks. At the GMDS assessment, nine (31%) participants had detectable VL and 26 (90%) had World Health Organization (WHO) clinical stage I disease. The GMDS was performed at a mean age of 11.5 ± 0.8 months. Mean quotients were within the average range: Global Griffiths score was 103.6 ± 10.9 and mean quotients on the subscales ranged from lowest 95.9 ± 13.4 for locomotor to highest 112.8 ± 11.3 for hearing-and-language. Conclusion: Preliminary findings in this small group suggest that early neurodevelopmental scores are within the normal range in infants with perinatal HIV infection who started ART at a median of 6 days.en_ZA
dc.description.versionPublisher's version
dc.format.extent8 pagesen_ZA
dc.identifier.citationLaughton, B. et al. 2019. Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life. Southern African Journal of HIV Medicine, 20(1):a1008, doi:10.4102/sajhivmed.v20i1.1008.
dc.identifier.issn2078-6751 (online)
dc.identifier.issn1608-9693 (print)
dc.identifier.otherdoi:10.4102/sajhivmed.v20i1.1008
dc.identifier.urihttp://hdl.handle.net/10019.1/107667
dc.language.isoen_ZAen_ZA
dc.publisherAOSISen_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectHIV infectionsen_ZA
dc.subjectAids (Desease) in infantsen_ZA
dc.subjectAntiretroviral agentsen_ZA
dc.subjectChildren -- Neurodevelopmenten_ZA
dc.subjectPaediatricsen_ZA
dc.titleNeurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of lifeen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
laughton_neurodevelopment_2019.pdf
Size:
676.99 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Paediatrics and Child Health)